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Unfortunately, no control of the CSF was obtained because the
patient left Paris and returned to Niger.
This report documents subacute polyradiculoneuritis due to
confirmed syphilis in a non-HIV-infected African patient. He
presented with symptoms mimicking Guillain–Barre´’s syn-
drome in association with bilateral Argyll Robertson’s sign,
hypergammaglobulinemia in the CSF and positivity of both
TPHA and the TPHA index 100 in the CSF [7].
The clinical presentation of neurosyphilis has changed.
Indeed, classical forms such as general paresis and tabes dorsalis
have decreased, while meningovascular and meningo-
encephalitis forms have increased in frequency, especially in
HIV-infected patients [7,8]. In contrast, syphilitic poly-
radiculoneuropathy has rarely been reported (Table 1). Lanska
et al [4] described an HIV-infected man in whom syphilitic
polyradiculopathy occurred 4 months after the rash of secondary
syphilis. Two other cases have been recently described in HIV-
negative patients. In one, polyradiculopathy occurred simul-
taneously with a maculopapular rash [5]. In the other, a tertiary
or late symptomatic neurosyphilis presented as a motor poly-
radiculoneuropathy without any previous skin rash [6]. All these
three cases recovered after penicillin therapy.
In conclusion, infection due to T. pallidum is a curable
cause of polyradiculoneuritis which may occur in HIV-negative
patients; appropriate tests in both serum and CSF should be
performed in patients with polyradiculoneuritis.
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Revision of quality control limits for cefotaxime disk susceptibility
tests
In the past few years, we have experienced difficulty when
cefotaxime disks were tested against the control strain of Strep-
tococcus pneumoniae (ATCC 49619), because zones were fre-
quently too large. As part of a recent multilaboratory study, we
were able to re-evaluate the quality control ranges for cefot-
axime disks tested against five different control strains, including
S. pneumoniae ATCC 49619.
The 10 participating laboratories are identified in the
Acknowledgments. Each participant was provided with agar
plates containing Mueller–Hinton agars from three different
manufacturers (Acumedia lot 9808187, Difco lot 107846JG and
BDMS lot 10 D1GE). For testing the pneumococcus, 5% sheep
blood was added to the agar media. For testing Haemophilus
influenzae, the Mueller–Hinton agars were prepared as Haemo-
philus Test Medium [1]. The participants were also provided
with 30-mg cefotaxime disks from two manufacturers (Remel
lot 30–836 5502 and BDMS lot 711558). Either cefaclor
(BDMS lot 1006610611) or cefixime (Remel lot 30–134 5508)
disks were used for internal control purposes. If zones around
the control disks were not within the established limits, the tests
were to be repeated, and if they remained out of control,
cefotaxime zones produced on that test plate were excluded
from our analysis. Because of space limitations, a Pseudomonas-
active control disk could not be tested against Pseudomonas
aeruginosa ATCC 27853, but only two of 600 cefotaxime zones
were outside the current control range of 18–22 mm [2] and
no changes are proposed.
Each participant independently tested all five control strains
on 10 different test days, following the disk test procedure
of the National Committee for Clinical Laboratory Standards
(NCCLS) [1]. On each test day, one inoculum suspension was
prepared for each control strain and the turbidity was adjusted
to match that of a McFarland 0.5 turbidity standard. Then,
three agar plates were inoculated, each from a different lot of
Mueller–Hinton agar. Each plate received two 30-mg cefot-
axime disks and one control disk (5 mg of cefixime or 30 mg of
cefaclor). The test plates were incubated for 18–20 h at 35 °C
in ambient air or for 20–24 h in 5–10% CO2 for the S. pneu-
moniae and H. influenzae control strains [1]. In this way, all 10
laboratories reported 600 cefotaxime zone diameters for each
control strain. Unsatisfactory control disk results excluded 0.3–
3.3% of those determinations. The excluded cefotaxime zones
were all within the current or proposed control ranges for
cefotaxime disk tests.
The results of this exercise are summarized in Table 1. The
current control ranges for 30-mg cefotaxime disk tests [2] against
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Table 1 Results of a 10-laboratory collaborative study to reassess quality control limits for cefotaxime disk susceptibility tests
Current quality control limits Observed zone diameters
No. zones
Control strain evaluateda Rangeb Midpoint Median (mm) % in range
Pseudomonas aeruginosa ATCC 27853 600 18–22 20 21 99.7%
Escherichia coli ATCC 25922 592 29–35 32 33 97.8%
Staphylococcus aureus ATCC 25923 580 25–31 28 28 98.6%
Haemophilus influenzae ATCC 49247 580 31–39 35 34 98.1%
Streptococcus pneumoniae ATCC 49619
NCCLS quality control limits 598 30–35 32.5 35 60.2%
Proposed range 598 31–39 35 35 96.3%
a Of the 600 determinations, some tests were excluded because the control disk gave zones outside of the established control ranges: for
different control strains, 3.3–0.3% of all cefotaxime zones were excluded. The control disk for the Streptococcus pneumoniae and Haemophilus
influenzae strains was cefixime, whereas cefaclor was the control disk for the Staphylococcus aureus and Escherichia coli strains. A
pseudomonas-active control disk could not be included because of space limitations. b Range of acceptable zone diameters (mm) listed in the
current NCCLS document, M100-S9 [2]. For Streptococcus pneumoniae ATCC 49619, an alternative control range is also listed. The midpoint
between the upper and lower limits is an idealized target value.
four of the five control strains were reconfirmed, since 98.1–
99.7% of the 600 zones fell within the established ranges and
the modal values were within 1 mm of the midpoint between
the two extremes. This included a narrow 5-mm range for P.
aeruginosa ATCC 27853 and a broader 9-mm range for H.
influenzae ATCC 49247. However, when S. pneumoniae ATCC
49619 was tested on Mueller–Hinton blood agar, only 60% of
the zones were within the narrow 6-mm range of 30–35 mm,
and the modal value was at the outer limit of 35 mm. The
current zone size limits are clearly inappropriate, and we pro-
pose a broader range of 31–39 mm for the S. pneumoniae control
strain. For that strain, other extended-spectrum cephalosporins
have 7- or 8-mm ranges [2], and this is compatible with the 9-
mm range that we are proposing for cefotaxime disk tests. Our
proposed change in zone size limits has recently been approved
by the NCCLS subcommittee on antimicrobial susceptibility
tests, and the new limits will appear in future NCCLS publi-
cations. This report describes the data that supported that
change in QC limits.
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Ascites and pleural effusion accompanying hepatitis A infection in
a child
Up to 1992, seven children were reported with acute hepatitis
A associated with ascites [1–3]. Pleural effusion also represents
a rare complication of acute type A viral hepatitis [4]. I report
a recent observation on a rare presentation of both ascites and
pleural effusion accompanying hepatitis A infection in a child.
A 4-year-old boy was hospitalized because of abdominal
distension and jaundice of the skin and sclerae. Four days earlier,
